Storia della carriera di Lisa M. Bell
Precedenti posizioni note di Lisa M. Bell
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| COHERUS BIOSCIENCES, INC. | Consigliere Generale | 12/05/2014 | 01/12/2017 |
Abbott Biotherapeutics Corp.
 Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | Consigliere Generale | - | - |
| BIOMARIN PHARMACEUTICAL INC. | Consigliere Generale | - | - |
Formazione di Lisa M. Bell
| University of California, Berkeley | Doctorate Degree |
| Boston University | Graduate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 5 |
| Israele | 2 |
Posizioni
| General Counsel | 3 |
| Doctorate Degree | 1 |
| Graduate Degree | 1 |
Settori
| Health Technology | 4 |
| Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| COHERUS BIOSCIENCES, INC. | Health Technology |
| BIOMARIN PHARMACEUTICAL INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | Health Technology |
- Borsa valori
- Insiders
- Lisa M. Bell
- Esperienza
